Mydecine 2022 Predictions: “Scaling revolves around three things…”
Mydecine Innovations Group (NEO: MYCO)(OTCMKTS: MYCOF) has filed multiple patents over the last two months covering multiple families of psilocin analogs. The biotechnology and digital technology company is aiming to transform the treatment of mental health and addiction disorders. These recent developments are a positive step towards that goal.
Two concerns with psilocybin as it stands in nature are wide variability in onset time between patients when administered orally, and poor shelf stability. Mydecine is in the process of solving for both, with applications that address further precision in delivery control and shelf stabilization–both of which are critical for use in the medical setting.
First, how do they deliver psilocin, psilocybin’s active metabolite, precisely? “Make it skin permeable,” says Rob Roscow, Chief Science Officer. The purpose of Mydecine’s dermal route for the administration of psilocin could eliminate undesirable properties like nausea by bypassing the digestive system, as well as eliminate variability concerns that make it more difficult to standardize protocols and scale treatments. If you take psilocybin or psilocin as they stand in nature and put them on your skin, nothing is going to happen. The normal paradigm with psilocybin is that it’s orally ingested and needs to be metabolized through the gut. This is highly variable from person to person, which is why it’s better to deliver psilocin to the blood. “This could be accomplished with an injectable, but we don’t feel that is a good fit for use in a mental health setting,” he says. “We can get the same effects with a transdermal, or through the skin, route of administration.”
Mydecine’s AI-Driven Drug Discovery Program
The company’s AI technology enhances their current research by aiding as a strong filter to Mydecine’s molecular designs. “As a company, when you think about how to actually do the research to figure out which options are better for a new drug or medication, a lot of testing is required,” says Roscow. “The AI is a funnel so only the best options for viable drug development are being further explored.” No time or resources are wasted. The AI technology is part of a joint research venture with Applied Pharmaceutical Innovation (API) that has allowed Mydecine to scale faster than without.
Technology Patent: What Is Nanoemulsion Technology?
Nanoemulsion technology is the concept of taking complex molecules and surrounding them with other molecules to make them more homogenous so they stay dispersed in a liquid, as explained by Roscow. “Think of nano-emulsification as allowing products of nature to be easily used in medicine. When you inject some of these compounds, the bioavailability isn’t very high,” he says. All to say, they get degraded before they get to their intended target or purpose. “Raising the bioavailability makes these ingredients more efficacious in over the counter or prescription medications.” Mydecine is also interested in the mutually-efficacious ingredients in functional mushrooms, like reishi or cordyceps.
Why Should Investors Be Excited About This News?
The ability to make valuable, expensive, and already accepted ingredients four to five times more effective is a strong improvement. “Raw ingredients are able to be stretched further,” Roscow says. “It reduces its waste on its transit to its destination.”
What Are The Top Things Companies Need To Be Considering As They Move Towards Monetizing Their Products?
Roscow says scaling revolves around three things: acceptance by the broader medical community; the necessary training for medical professionals to provide new therapies; and the insurance side, which might be less exciting than the patient side but important logistically. He believes that by addressing these three areas, psychedelics will move from something that is currently being looked at as “novel and special,” and put it on the same playing field as currently accepted therapies.
Why Consider Investing In The Psychedelics Industry?
“I was trained as a developmental biologist and it was driven home to me that as an adult, you have little to no potential to regrow neuron connections,” says Roscow. “These drugs really fly in the face of that. They allow new neuron growth and connections. The excitement is then paring that with therapy.”
Looking Ahead To 2022
Mydecine is launching two clinical trials in partnership with Johns Hopkins looking at nicotine addiction, and secondarily, looking at psilocybin matched with therapy. This is precisely what the future needs.
For more on Mydecine’s 2022 projections, watch the interview above.